Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Assets Average (2016 - 2025)

Historic Assets Average for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $563.5 million.

  • Adma Biologics' Assets Average rose 4694.16% to $563.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $563.5 million, marking a year-over-year increase of 4694.16%. This contributed to the annual value of $408.9 million for FY2024, which is 2069.19% up from last year.
  • Per Adma Biologics' latest filing, its Assets Average stood at $563.5 million for Q3 2025, which was up 4694.16% from $534.5 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Assets Average registered a high of $563.5 million during Q3 2025, and its lowest value of $221.7 million during Q1 2021.
  • Moreover, its 5-year median value for Assets Average was $340.0 million (2024), whereas its average is $350.7 million.
  • In the last 5 years, Adma Biologics' Assets Average plummeted by 133.36% in 2024 and then skyrocketed by 4698.02% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Assets Average stood at $257.4 million in 2021, then grew by 26.05% to $324.5 million in 2022, then increased by 4.49% to $339.1 million in 2023, then increased by 29.66% to $439.6 million in 2024, then rose by 28.18% to $563.5 million in 2025.
  • Its Assets Average was $563.5 million in Q3 2025, compared to $534.5 million in Q2 2025 and $499.6 million in Q1 2025.